Scott Kopetz

List of Publications by Citations

525 papers	28,226 citations	81 h-index	157 g-index
650 ext. papers	35,348 ext. citations	5.5 avg, IF	7.02 L-index

#	Paper	IF	Citations
525	The consensus molecular subtypes of colorectal cancer. *Nature Medicine*, **2015**, 21, 1350-6	50.5	2332
524	Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. *Lancet Oncology, The*, **2017**, 18, 1182-1191	21.7	1317
523	Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. *Journal of Clinical Oncology*, **2009**, 27, 3677-83	2.2	955
522	Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer. *Journal of Clinical Oncology*, **2018**, 36, 773-779	2.2	938
521	Towards the introduction of the 'Immunoscore' in the classification of malignant tumours. *Journal of Pathology*, **2014**, 232, 199-209	9.4	882
520	Cancer classification using the Immunoscore: a worldwide task force. *Journal of Translational Medicine*, **2012**, 10, 205	8.5	538
519	Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer. *Cancer*, **2011**, 117, 4623-32	6.4	492
518	Encorafenib, Binimetinib, and Cetuximab in V600E-Mutated Colorectal Cancer. *New England Journal of Medicine*, **2019**, 381, 1632-1643	59.2	481
517	Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. *Journal of Clinical Oncology*, **2008**, 26, 5344-51	2.2	458
516	CCAT2, a novel noncoding RNA mapping to 8q24, underlies metastatic progression and chromosomal instability in colon cancer. *Genome Research*, **2013**, 23, 1446-61	9.7	442
515	Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNA. *PLoS ONE*, **2015**, 10, e0140712	3.7	442
514	Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer. *Journal of Clinical Oncology*, **2015**, 33, 4032-8	2.2	424
513	Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer. *Nature Reviews Cancer*, **2017**, 17, 79-92	31.3	423
512	Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. *Journal of Clinical Oncology*, **2010**, 28, 453-9	2.2	383
511	Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases. *JAMA - Journal of the American Medical Association*, **2009**, 302, 2338-44	27.4	373
510	Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer. *Journal of Clinical Oncology*, **2015**, 33, 4023-31	2.2	315
509	Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical Trials. *Journal of Clinical Oncology*, **2015**, 33, 2753-62	2.2	295

508	High survival rate after two-stage resection of advanced colorectal liver metastases: response-based selection and complete resection define outcome. *Journal of Clinical Oncology*, **2011**, 29, 1083-90	2.2	293
507	Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO-ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS. *Annals of Oncology*, **2018**, 29, 44-70	10.3	260
506	Blood neutrophil-to-lymphocyte ratio predicts survival in patients with colorectal liver metastases treated with systemic chemotherapy. *Annals of Surgical Oncology*, **2009**, 16, 614-22	3.1	260
505	RAS mutation status predicts survival and patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases. *Annals of Surgery*, **2013**, 258, 619-26; discussion 626-7	7.8	251
504	Beyond VEGF: inhibition of the fibroblast growth factor pathway and antiangiogenesis. *Clinical Cancer Research*, **2011**, 17, 6130-9	12.9	225
503	ALDH activity selectively defines an enhanced tumor-initiating cell population relative to CD133 expression in human pancreatic adenocarcinoma. *PLoS ONE*, **2011**, 6, e20636	3.7	211
502	Use of research biopsies in clinical trials: are risks and benefits adequately discussed?. *Journal of Clinical Oncology*, **2013**, 31, 17-22	2.2	210
501	Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents. *Clinical Cancer Research*, **2013**, 19, 657-67	12.9	205
500	Surgical strategies for synchronous colorectal liver metastases in 156 consecutive patients: classic, combined or reverse strategy?. *Journal of the American College of Surgeons*, **2010**, 210, 934-41	4.4	204
499	Platelets and cancer: a casual or causal relationship: revisited. *Cancer and Metastasis Reviews*, **2014**, 33, 231-69	9.6	195
498	Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and the American Society of Clinical Oncology. *Journal of Clinical Oncology*, **2017**, 35, 1453-1486	2.2	191
497	KRAS-IRF2 Axis Drives Immune Suppression and Immune Therapy Resistance in Colorectal Cancer. *Cancer Cell*, **2019**, 35, 559-572.e7	24.3	187
496	Extended preoperative chemotherapy does not improve pathologic response and increases postoperative liver insufficiency after hepatic resection for colorectal liver metastases. *Annals of Surgical Oncology*, **2010**, 17, 2870-6	3.1	186
495	BRAF Mutations Define a Clinically Distinct Molecular Subtype of Metastatic Colorectal Cancer. *Journal of Clinical Oncology*, **2017**, 35, 2624-2630	2.2	176
494	Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment. *Annals of Oncology*, **2015**, 26, 731-736	10.3	175
493	Multicenter retrospective analysis of metastatic colorectal cancer (CRC) with high-level microsatellite instability (MSI-H). *Annals of Oncology*, **2014**, 25, 1032-8	10.3	174
492	Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer. *Cancer Research*, **2012**, 72, 779-89	10.1	172
491	Phase II study of capecitabine and oxaliplatin for advanced adenocarcinoma of the small bowel and ampulla of Vater. *Journal of Clinical Oncology*, **2009**, 27, 2598-603	2.2	167

490	Optimal morphologic response to preoperative chemotherapy: an alternate outcome end point before resection of hepatic colorectal metastases. *Journal of Clinical Oncology*, **2012**, 30, 4566-72	2.2	163
489	Right Versus Left Colon Cancer Biology: Integrating the Consensus Molecular Subtypes. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2017**, 15, 411-419	7.3	161
488	Epithelial-mesenchymal transitioned circulating tumor cells capture for detecting tumor progression. *Clinical Cancer Research*, **2015**, 21, 899-906	12.9	158
487	Preoperative bevacizumab does not significantly increase postoperative complication rates in patients undergoing hepatic surgery for colorectal cancer liver metastases. *Journal of Clinical Oncology*, **2008**, 26, 5254-60	2.2	153
486	Oxaliplatin-mediated increase in spleen size as a biomarker for the development of hepatic sinusoidal injury. *Journal of Clinical Oncology*, **2010**, 28, 2549-55	2.2	151
485	Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAFV600E Mutation. *Cancer Discovery*, **2016**, 6, 1352-1365	24.4	150
484	Genomic Landscape of Cell-Free DNA in Patients with Colorectal Cancer. *Cancer Discovery*, **2018**, 8, 164-173	24.4	148
483	Classifying Colorectal Cancer by Tumor Location Rather than Sidedness Highlights a Continuum in Mutation Profiles and Consensus Molecular Subtypes. *Clinical Cancer Research*, **2018**, 24, 1062-1072	12.9	143
482	Margin status remains an important determinant of survival after surgical resection of colorectal liver metastases in the era of modern chemotherapy. *Annals of Surgery*, **2013**, 257, 1079-88	7.8	138
481	A decision support framework for genomically informed investigational cancer therapy. *Journal of the National Cancer Institute*, **2015**, 107,	9.7	135
480	Systemic chemotherapy and two-stage hepatectomy for extensive bilateral colorectal liver metastases: perioperative safety and survival. *Journal of Gastrointestinal Surgery*, **2007**, 11, 1498-504; discussion 1504-5	3.3	135
479	PLX4032 in metastatic colorectal cancer patients with mutant BRAF tumors.. *Journal of Clinical Oncology*, **2010**, 28, 3534-3534	2.2	135
478	Meta-analysis of KRAS mutations and survival after resection of colorectal liver metastases. *British Journal of Surgery*, **2015**, 102, 1175-83	5.3	133
477	Return to intended oncologic treatment (RIOT): a novel metric for evaluating the quality of oncosurgical therapy for malignancy. *Journal of Surgical Oncology*, **2014**, 110, 107-14	2.8	129
476	Single-cell DNA sequencing reveals a late-dissemination model in metastatic colorectal cancer. *Genome Research*, **2017**, 27, 1287-1299	9.7	127
475	The promise of patient-derived xenografts: the best laid plans of mice and men. *Clinical Cancer Research*, **2012**, 18, 5160-2	12.9	127
474	Disparity of Race Reporting and Representation in Clinical Trials Leading to Cancer Drug Approvals From 2008 to 2018. *JAMA Oncology*, **2019**, 5, e191870	13.4	126
473	Immune profiling of human tumors identifies CD73 as a combinatorial target in glioblastoma. *Nature Medicine*, **2020**, 26, 39-46	50.5	119

472	Potential role of nuclear PD-L1 expression in cell-surface vimentin positive circulating tumor cells as a prognostic marker in cancer patients. *Scientific Reports*, **2016**, 6, 28910	4.9	116
471	Molecular profiling of patient-matched brain and extracranial melanoma metastases implicates the PI3K pathway as a therapeutic target. *Clinical Cancer Research*, **2014**, 20, 5537-46	12.9	115
470	Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With V600E-Mutant Metastatic Colorectal Cancer: Safety Lead-In Results From the Phase III BEACON Colorectal Cancer Study. *Journal of Clinical Oncology*, **2019**, 37, 1460-1469	2.2	114
469	Synergistic activity of the SRC family kinase inhibitor dasatinib and oxaliplatin in colon carcinoma cells is mediated by oxidative stress. *Cancer Research*, **2009**, 69, 3842-9	10.1	112
468	Clinical and molecular characterization of early-onset colorectal cancer. *Cancer*, **2019**, 125, 2002-2010	6.4	110
467	Incidental germline variants in 1000 advanced cancers on a prospective somatic genomic profiling protocol. *Annals of Oncology*, **2016**, 27, 795-800	10.3	107
466	How liquid biopsies can change clinical practice in oncology. *Annals of Oncology*, **2019**, 30, 1580-1590	10.3	107
465	Topoisomerase II in chromosome instability and personalized cancer therapy. *Oncogene*, **2015**, 34, 4019-31	9.1	105
464	Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challenge. *Annals of Oncology*, **2019**, 30, 243-249	10.3	105
463	Biomarker-guided therapy for colorectal cancer: strength in complexity. *Nature Reviews Clinical Oncology*, **2020**, 17, 11-32	19.4	103
462	Significant association of oncogene YAP1 with poor prognosis and cetuximab resistance in colorectal cancer patients. *Clinical Cancer Research*, **2015**, 21, 357-64	12.9	101
461	The clinical and biological significance of MIR-224 expression in colorectal cancer metastasis. *Gut*, **2016**, 65, 977-989	19.2	99
460	Cytokine profile and prognostic significance of high neutrophil-lymphocyte ratio in colorectal cancer. *British Journal of Cancer*, **2015**, 112, 1088-97	8.7	99
459	Platelet "first responders" in wound response, cancer, and metastasis. *Cancer and Metastasis Reviews*, **2017**, 36, 199-213	9.6	98
458	Chemotherapy with 5-fluorouracil and a platinum compound improves outcomes in metastatic small bowel adenocarcinoma. *Cancer*, **2008**, 113, 2038-45	6.4	95
457	Src continues aging: current and future clinical directions. *Clinical Cancer Research*, **2007**, 13, 7232-6	12.9	94
456	Immunophenotype and molecular characterisation of adenocarcinoma of the small intestine. *British Journal of Cancer*, **2010**, 102, 144-50	8.7	93
455	Liquid Biopsies Using Plasma Exosomal Nucleic Acids and Plasma Cell-Free DNA Compared with Clinical Outcomes of Patients with Advanced Cancers. *Clinical Cancer Research*, **2018**, 24, 181-188	12.9	89

454	A population-based comparison of adenocarcinoma of the large and small intestine: insights into a rare disease. *Annals of Surgical Oncology*, **2012**, 19, 1439-45	3.1	89
453	BRAF mutant colorectal cancer as a distinct subset of colorectal cancer: clinical characteristics, clinical behavior, and response to targeted therapies. *Journal of Gastrointestinal Oncology*, **2015**, 6, 660-7	2.8	88
452	Long-term survival and recurrence outcomes following surgery for distal rectal cancer. *Annals of Surgical Oncology*, **2010**, 17, 2863-9	3.1	87
451	PRMT1-mediated methylation of the EGF receptor regulates signaling and cetuximab response. *Journal of Clinical Investigation*, **2015**, 125, 4529-43	15.9	85
450	Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG 1406).. *Journal of Clinical Oncology*, **2017**, 35, 520-520	2.2	85
449	Streptococcus gallolyticus subsp. gallolyticus promotes colorectal tumor development. *PLoS Pathogens*, **2017**, 13, e1006440	7.6	85
448	The association of alternate VEGF ligands with resistance to anti-VEGF therapy in metastatic colorectal cancer. *PLoS ONE*, **2013**, 8, e77117	3.7	84
447	ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal-Anal Task Forces whitepaper. *Nature Reviews Clinical Oncology*, **2020**, 17, 757-770	19.4	82
446	RAS Mutation Predicts Positive Resection Margins and Narrower Resection Margins in Patients Undergoing Resection of Colorectal Liver Metastases. *Annals of Surgical Oncology*, **2016**, 23, 2635-43	3.1	82
445	Oncogenic drives invasion and maintains metastases in colorectal cancer. *Genes and Development*, **2017**, 31, 370-382	12.6	80
444	RAS mutations predict radiologic and pathologic response in patients treated with chemotherapy before resection of colorectal liver metastases. *Annals of Surgical Oncology*, **2015**, 22, 834-842	3.1	79
443	Genomic classifier ColoPrint predicts recurrence in stage II colorectal cancer patients more accurately than clinical factors. *Oncologist*, **2015**, 20, 127-33	5.7	79
442	Deleterious Effect of RAS and Evolutionary High-risk TP53 Double Mutation in Colorectal Liver Metastases. *Annals of Surgery*, **2019**, 269, 917-923	7.8	78
441	Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts **2019**, 7, 37		77
440	Progression-free survival remains poor over sequential lines of systemic therapy in patients with BRAF-mutated colorectal cancer. *Clinical Colorectal Cancer*, **2014**, 13, 164-71	3.8	77
439	Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies. *Oncotarget*, **2015**, 6, 12809-21	3.3	77
438	Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical Oncology. *Journal of Molecular Diagnostics*, **2017**, 19, 187-225	5.1	76
437	Clinical actionability enhanced through deep targeted sequencing of solid tumors. *Clinical Chemistry*, **2015**, 61, 544-53	5.5	76

436	Portal hypertension associated with oxaliplatin administration: clinical manifestations of hepatic sinusoidal injury. *Clinical Colorectal Cancer*, **2009**, 8, 225-30	3.8	76
435	N-BLR, a primate-specific non-coding transcript leads to colorectal cancer invasion and migration. *Genome Biology*, **2017**, 18, 98	18.3	75
434	Genomic landscape associated with potential response to anti-CTLA-4 treatment in cancers. *Nature Communications*, **2017**, 8, 1050	17.4	75
433	Non-coding RNAs in GI cancers: from cancer hallmarks to clinical utility. *Gut*, **2020**, 69, 748-763	19.2	74
432	Evidence for the efficacy of Iniparib, a PARP-1 inhibitor, in BRCA2-associated pancreatic cancer. *Anticancer Research*, **2011**, 31, 1417-20	2.3	74
431	Characteristics and outcomes of dementia residents in an assisted living facility. *International Journal of Geriatric Psychiatry*, **2000**, 15, 586-93	3.9	73
430	Validation of Microsatellite Instability Detection Using a Comprehensive Plasma-Based Genotyping Panel. *Clinical Cancer Research*, **2019**, 25, 7035-7045	12.9	72
429	Efficacy of the combination of MEK and CDK4/6 inhibitors in vitro and in vivo in KRAS mutant colorectal cancer models. *Oncotarget*, **2016**, 7, 39595-39608	3.3	72
428	5-fluorouracil resistant colon cancer cells are addicted to OXPHOS to survive and enhance stem-like traits. *Oncotarget*, **2015**, 6, 41706-21	3.3	71
427	Phase 1 study of TAS-102 administered once daily on a 5-day-per-week schedule in patients with solid tumors. *Investigational New Drugs*, **2008**, 26, 445-54	4.3	70
426	Nivolumab ipilimumab in treatment (tx) of patients (pts) with metastatic colorectal cancer (mCRC) with and without high microsatellite instability (MSI-H): CheckMate-142 interim results.. *Journal of Clinical Oncology*, **2016**, 34, 3501-3501	2.2	70
425	Mutation Status of , and is Superior to Mutation Status of Alone for Predicting Prognosis after Resection of Colorectal Liver Metastases. *Clinical Cancer Research*, **2019**, 25, 5843-5851	12.9	69
424	Prognostic gene expression signature associated with two molecularly distinct subtypes of colorectal cancer. *Gut*, **2012**, 61, 1291-8	19.2	69
423	Local tumour progression after percutaneous ablation of colorectal liver metastases according to RAS mutation status. *British Journal of Surgery*, **2017**, 104, 760-768	5.3	68
422	Recent developments in the treatment of metastatic colorectal cancer. *Therapeutic Advances in Medical Oncology*, **2017**, 9, 551-564	5.4	68
421	Is there a role for adjuvant therapy in resected adenocarcinoma of the small intestine. *Acta Oncologica*, **2010**, 49, 474-9	3.2	68
420	Src family kinases as mediators of endothelial permeability: effects on inflammation and metastasis. *Cell and Tissue Research*, **2009**, 335, 249-59	4.2	68
419	Hotspot mutation panel testing reveals clonal evolution in a study of 265 paired primary and metastatic tumors. *Clinical Cancer Research*, **2015**, 21, 2644-51	12.9	63

418	Combined targeting of STAT3/NF-ΚB/COX-2/EP4 for effective management of pancreatic cancer. *Clinical Cancer Research*, **2014**, 20, 1259-73	12.9	63
417	Examining plasma microRNA markers for colorectal cancer at different stages. *Oncotarget*, **2016**, 7, 11434-49	5.3	63
416	Perioperative chemotherapy for resectable hepatic metastases. *Lancet, The*, **2008**, 371, 963-5	40	62
415	BRAF Mutation Testing in Cell-Free DNA from the Plasma of Patients with Advanced Cancers Using a Rapid, Automated Molecular Diagnostics System. *Molecular Cancer Therapeutics*, **2016**, 15, 1397-404	6.1	61
414	Association between KRAS mutation and lung metastasis in advanced colorectal cancer. *British Journal of Cancer*, **2015**, 112, 424-8	8.7	61
413	Tumor thickness at the tumor-normal interface: a novel pathologic indicator of chemotherapy response in hepatic colorectal metastases. *American Journal of Surgical Pathology*, **2010**, 34, 1287-94	6.7	60
412	Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated V600E-Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study. *Journal of Clinical Oncology*, **2021**, 39, 273-284	2.2	60
411	Therapeutic silencing of KRAS using systemically delivered siRNAs. *Molecular Cancer Therapeutics*, **2014**, 13, 2876-85	6.1	59
410	Phase I clinical study of three times a day oral administration of TAS-102 in patients with solid tumors. *Cancer Investigation*, **2008**, 26, 794-9	2.1	59
409	Circulating DNA Demonstrates Convergent Evolution and Common Resistance Mechanisms during Treatment of Colorectal Cancer. *Clinical Cancer Research*, **2017**, 23, 4578-4591	12.9	58
408	Association of CpG island methylator phenotype and EREG/AREG methylation and expression in colorectal cancer. *British Journal of Cancer*, **2016**, 114, 1352-61	8.7	58
407	The SRC family of protein tyrosine kinases: a new and promising target for colorectal cancer therapy. *Clinical Colorectal Cancer*, **2010**, 9, 89-94	3.8	58
406	Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical Oncology. *Archives of Pathology and Laboratory Medicine*, **2017**, 141, 625-657	5	54
405	Efficacy of Sym004 in Patients With Metastatic Colorectal Cancer With Acquired Resistance to Anti-EGFR Therapy and Molecularly Selected by Circulating Tumor DNA Analyses: A Phase 2 Randomized Clinical Trial. *JAMA Oncology*, **2018**, 4, e175245	13.4	54
404	Randomized Trial of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF-Mutant Metastatic Colorectal Cancer (SWOG S1406). *Journal of Clinical Oncology*, **2021**, 39, 285-294	2.2	53
403	Is complete liver resection without resection of synchronous lung metastases justified?. *Annals of Surgical Oncology*, **2015**, 22, 1585-92	3.1	52
402	Predictors of Safety and Efficacy of 2-Stage Hepatectomy for Bilateral Colorectal Liver Metastases. *Journal of the American College of Surgeons*, **2016**, 223, 99-108	4.4	52
401	Adjuvant chemotherapy with FOLFOX for primary colorectal cancer is associated with increased somatic gene mutations and inferior survival in patients undergoing hepatectomy for metachronous liver metastases. *Annals of Surgery*, **2012**, 256, 642-50	7.8	51

400	Expanded RAS: refining the patient population. *Journal of Clinical Oncology*, **2015**, 33, 682-5	2.2	50
399	FXR silencing in human colon cancer by DNA methylation and KRAS signaling. *American Journal of Physiology - Renal Physiology*, **2014**, 306, G48-58	5.1	49
398	Association of SMAD4 mutation with patient demographics, tumor characteristics, and clinical outcomes in colorectal cancer. *PLoS ONE*, **2017**, 12, e0173345	3.7	49
397	HER2 amplification as a negative predictive biomarker for anti-epidermal growth factor receptor antibody therapy in metastatic colorectal cancer.. *Journal of Clinical Oncology*, **2016**, 34, 3517-3517	2.2	48
396	Embryonic Origin of Primary Colon Cancer Predicts Pathologic Response and Survival in Patients Undergoing Resection for Colon Cancer Liver Metastases. *Annals of Surgery*, **2018**, 267, 514-520	7.8	46
395	Sacral insufficiency fractures after preoperative chemoradiation for rectal cancer: incidence, risk factors, and clinical course. *International Journal of Radiation Oncology Biology Physics*, **2009**, 74, 818-23	4	46
394	SMAD4 gene mutation predicts poor prognosis in patients undergoing resection for colorectal liver metastases. *European Journal of Surgical Oncology*, **2018**, 44, 684-692	3.6	45
393	Mutation-Enrichment Next-Generation Sequencing for Quantitative Detection of Mutations in Urine Cell-Free DNA from Patients with Advanced Cancers. *Clinical Cancer Research*, **2017**, 23, 3657-3666	12.9	44
392	Gene expression profiling of ampullary carcinomas classifies ampullary carcinomas into biliary-like and intestinal-like subtypes that are prognostic of outcome. *PLoS ONE*, **2013**, 8, e65144	3.7	44
391	Clinical findings of a palliative care consultation team at a comprehensive cancer center. *Journal of Palliative Medicine*, **2008**, 11, 191-7	2.2	44
390	Platelets, circulating tumor cells, and the circulome. *Cancer and Metastasis Reviews*, **2017**, 36, 235-248	9.6	43
389	BRAF inhibitors: experience in thyroid cancer and general review of toxicity. *Hormones and Cancer*, **2015**, 6, 21-36	5	43
388	Partial splenic embolization for cancer patients with thrombocytopenia requiring systemic chemotherapy. *Cancer*, **2008**, 112, 2283-8	6.4	43
387	Mechanisms of Innate and Acquired Resistance to Anti-EGFR Therapy: A Review of Current Knowledge with a Focus on Rechallenge Therapies. *Clinical Cancer Research*, **2019**, 25, 6899-6908	12.9	42
386	Nivolumab in patients with DNA mismatch repair deficient/microsatellite instability high metastatic colorectal cancer: Update from CheckMate 142.. *Journal of Clinical Oncology*, **2017**, 35, 519-519	2.2	42
385	TMEM9 promotes intestinal tumorigenesis through vacuolar-ATPase-activated Wnt/β-catenin signalling. *Nature Cell Biology*, **2018**, 20, 1421-1433	23.4	42
384	Circulating tumor markers: harmonizing the yin and yang of CTCs and ctDNA for precision medicine. *Annals of Oncology*, **2017**, 28, 468-477	10.3	41
383	Extended RAS analysis for anti-epidermal growth factor therapy in patients with metastatic colorectal cancer. *Cancer Treatment Reviews*, **2015**, 41, 653-9	14.4	41

382	Durable complete responses in metastatic colorectal cancer treated with chemotherapy alone. *Clinical Colorectal Cancer*, **2011**, 10, 178-82	3.8	41
381	Immune Profiling of Premalignant Lesions in Patients With Lynch Syndrome. *JAMA Oncology*, **2018**, 4, 1085-1092	13.4	40
380	Relative Abundance of SARS-CoV-2 Entry Genes in the Enterocytes of the Lower Gastrointestinal Tract. *Genes*, **2020**, 11,	4.2	39
379	Impact of Recurrence and Salvage Surgery on Survival After Multidisciplinary Treatment of Rectal Cancer. *Journal of Clinical Oncology*, **2017**, 35, 2631-2638	2.2	39
378	GWAS-identified colorectal cancer susceptibility loci associated with clinical outcomes. *Carcinogenesis*, **2012**, 33, 1327-31	4.6	39
377	Quantified pathologic response assessed as residual tumor burden is a predictor of recurrence-free survival in patients with rectal cancer who undergo resection after neoadjuvant chemoradiotherapy. *Cancer*, **2013**, 119, 4231-41	6.4	39
376	Predictive and prognostic markers in colorectal cancer. *Current Oncology Reports*, **2011**, 13, 206-15	6.3	39
375	MicroRNAs, ultraconserved genes and colorectal cancers. *International Journal of Biochemistry and Cell Biology*, **2010**, 42, 1291-7	5.6	39
374	FBXW7 missense mutation: a novel negative prognostic factor in metastatic colorectal adenocarcinoma. *Oncotarget*, **2017**, 8, 39268-39279	3.3	39
373	MET amplification in metastatic colorectal cancer: an acquired response to EGFR inhibition, not a de novo phenomenon. *Oncotarget*, **2016**, 7, 54627-54631	3.3	39
372	Development and Validation of an Ultradeep Next-Generation Sequencing Assay for Testing of Plasma Cell-Free DNA from Patients with Advanced Cancer. *Clinical Cancer Research*, **2017**, 23, 5648-5656	12.9	38
371	Clinicopathologic characteristics and gene expression analyses of non-KRAS 12/13, RAS-mutated metastatic colorectal cancer. *Annals of Oncology*, **2014**, 25, 2008-2014	10.3	38
370	Global and targeted serum metabolic profiling of colorectal cancer progression. *Cancer*, **2017**, 123, 4066-4074	6.4	38
369	Metastasis regulation by PPARD expression in cancer cells. *JCI Insight*, **2017**, 2, e91419	9.9	38
368	BRAF mutation testing with a rapid, fully integrated molecular diagnostics system. *Oncotarget*, **2015**, 6, 26886-94	3.3	38
367	Biomarkers in colorectal liver metastases. *British Journal of Surgery*, **2018**, 105, 618-627	5.3	37
366	Is hepatectomy justified for patients with RAS mutant colorectal liver metastases? An analysis of 524 patients undergoing curative liver resection. *Surgery*, **2017**, 161, 332-340	3.6	37
365	Conditional Recurrence-Free Survival after Resection of Colorectal Liver Metastases: Persistent Deleterious Association with RAS and TP53 Co-Mutation. *Journal of the American College of Surgeons*, **2019**, 229, 286-294.e1	4.4	36

364	Multicenter validation study of pathologic response and tumor thickness at the tumor-normal liver interface as independent predictors of disease-free survival after preoperative chemotherapy and surgery for colorectal liver metastases. *Cancer*, **2013**, 119, 2778-88	6.4	36
363	Multiplex KRASG12/G13 mutation testing of unamplified cell-free DNA from the plasma of patients with advanced cancers using droplet digital polymerase chain reaction. *Annals of Oncology*, **2017**, 28, 642-650	10.3	35
362	Clinical, Pathological, and Molecular Characteristics of CpG Island Methylator Phenotype in Colorectal Cancer: A Systematic Review and Meta-analysis. *Translational Oncology*, **2018**, 11, 1188-1201	4.9	35
361	Target-based therapeutic matching in early-phase clinical trials in patients with advanced colorectal cancer and PIK3CA mutations. *Molecular Cancer Therapeutics*, **2013**, 12, 2857-63	6.1	35
360	Individualized therapies in colorectal cancer: KRAS as a marker for response to EGFR-targeted therapy. *Journal of Hematology and Oncology*, **2009**, 2, 18	22.4	35
359	Blood-based tests for colorectal cancer screening: do they threaten the survival of the FIT test?. *Digestive Diseases and Sciences*, **2015**, 60, 664-71	4	34
358	Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG S1406).. *Journal of Clinical Oncology*, **2017**, 35, 3505-3505	2.2	34
357	The Long Noncoding RNA CCAT2 Induces Chromosomal Instability Through BOP1-AURKB Signaling. *Gastroenterology*, **2020**, 159, 2146-2162.e33	13.3	34
356	The somatic mutation landscape of premalignant colorectal adenoma. *Gut*, **2018**, 67, 1299-1305	19.2	33
355	Postoperative chemotherapy use after neoadjuvant chemoradiotherapy for rectal cancer: Analysis of Surveillance, Epidemiology, and End Results-Medicare data, 1998-2007. *Cancer*, **2014**, 120, 1162-70	6.4	33
354	Retreatment with anti-EGFR based therapies in metastatic colorectal cancer: impact of intervening time interval and prior anti-EGFR response. *BMC Cancer*, **2015**, 15, 713	4.8	33
353	Hyperfractionated accelerated reirradiation for rectal cancer: An analysis of outcomes and toxicity. *Radiotherapy and Oncology*, **2017**, 122, 146-151	5.3	32
352	Deep sequencing of circulating tumor DNA detects molecular residual disease and predicts recurrence in gastric cancer. *Cell Death and Disease*, **2020**, 11, 346	9.8	32
351	High-Grade Neuroendocrine Colorectal Carcinomas: A Retrospective Study of 100 Patients. *Clinical Colorectal Cancer*, **2016**, 15, e1-7	3.8	32
350	Phase I/II study of azacitidine and capecitabine/oxaliplatin (CAPOX) in refractory CIMP-high metastatic colorectal cancer: evaluation of circulating methylated vimentin. *Oncotarget*, **2016**, 7, 67495-67506	3.3	32
349	Endothelial function, oxidative stress and inflammatory studies in chronic coronary slow flow phenomenon patients. *Cardiology*, **2012**, 121, 197-203	1.6	31
348	Bevacizumab combined with capecitabine and oxaliplatin in patients with advanced adenocarcinoma of the small bowel or ampulla of vater: A single-center, open-label, phase 2 study. *Cancer*, **2017**, 123, 1011-1017	6.4	30
347	Dual Inhibition of EGFR and c-Src by Cetuximab and Dasatinib Combined with FOLFOX Chemotherapy in Patients with Metastatic Colorectal Cancer. *Clinical Cancer Research*, **2017**, 23, 4146-4154	12.9	29

346	CT findings of response and recurrence, independent of change in tumor size, in colorectal liver metastasis treated with bevacizumab. *American Journal of Roentgenology*, **2011**, 197, W1060-6	5.4	29
345	Combining curcumin (diferuloylmethane) and heat shock protein inhibition for neurofibromatosis 2 treatment: analysis of response and resistance pathways. *Molecular Cancer Therapeutics*, **2011**, 10, 2094-103	6.1	29
344	First in human phase I study of BSI-201, a small molecule inhibitor of poly ADP-ribose polymerase (PARP) in subjects with advanced solid tumors. *Journal of Clinical Oncology*, **2008**, 26, 3577-3577	2.2	29
343	BRAF inhibitors in clinical oncology. *F1000prime Reports*, **2013**, 5, 11		29
342	Molecular spectrum of , , , , , and somatic gene mutations in Arab patients with colorectal cancer: determination of frequency and distribution pattern. *Journal of Gastrointestinal Oncology*, **2016**, 7, 882-902	2.8	29
341	Back to the Colorectal Cancer Consensus Molecular Subtype Future. *Current Gastroenterology Reports*, **2019**, 21, 5	5	28
340	Phase II study of saracatinib (AZD0530) in patients with previously treated metastatic colorectal cancer. *Investigational New Drugs*, **2015**, 33, 977-84	4.3	28
339	Proteome Instability Is a Therapeutic Vulnerability in Mismatch Repair-Deficient Cancer. *Cancer Cell* , **2020**, 37, 371-386.e12	24.3	28
338	Genome-wide Discovery and Identification of a Novel miRNA Signature for Recurrence Prediction in Stage II and III Colorectal Cancer. *Clinical Cancer Research*, **2018**, 24, 3867-3877	12.9	28
337	Molecular Landscape of ERBB2/ERBB3 Mutated Colorectal Cancer. *Journal of the National Cancer Institute*, **2018**, 110, 1409-1417	9.7	28
336	The requirement for freshly isolated human colorectal cancer (CRC) cells in isolating CRC stem cells. *British Journal of Cancer*, **2015**, 112, 539-46	8.7	28
335	BEACON CRC study safety lead-in (SLI) in patients with BRAFV600E metastatic colorectal cancer (mCRC): Efficacy and tumor markers.. *Journal of Clinical Oncology*, **2018**, 36, 627-627	2.2	28
334	Prevalence of recurrent oncogenic fusion in mismatch repair-deficient colorectal carcinoma with hypermethylated MLH1 and wild-type BRAF and KRAS. *Modern Pathology*, **2019**, 32, 1053-1064	9.8	27
333	BRAF-Directed Therapy in Metastatic Colorectal Cancer. *Cancer Journal (Sudbury, Mass.)*, **2016**, 22, 175-8	2.2	27
332	Impact of multimodal therapy in locally recurrent rectal cancer. *British Journal of Surgery*, **2016**, 103, 753-762	5.3	27
331	Is resection of colorectal liver metastases after a second-line chemotherapy regimen justified?. *Cancer*, **2011**, 117, 4484-92	6.4	27
330	The potential role of platelets in the consensus molecular subtypes of colorectal cancer. *Cancer and Metastasis Reviews*, **2017**, 36, 273-288	9.6	26
329	Colorectal Cancer Subtyping Consortium (CRCSC) identification of a consensus of molecular subtypes.. *Journal of Clinical Oncology*, **2014**, 32, 3511-3511	2.2	26

328	Utility of a molecular prescreening program in advanced colorectal cancer for enrollment on biomarker-selected clinical trials. *Annals of Oncology*, **2016**, 27, 1068-1074	10.3	26
327	RAS Mutation Is Associated with Decreased Survival in Patients Undergoing Repeat Hepatectomy for Colorectal Liver Metastases. *Journal of Gastrointestinal Surgery*, **2017**, 21, 68-77	3.3	25
326	Severe obesity prior to diagnosis limits survival in colorectal cancer patients evaluated at a large cancer centre. *British Journal of Cancer*, **2016**, 114, 103-9	8.7	25
325	A retrospective study of ampullary adenocarcinomas: overall survival and responsiveness to fluoropyrimidine-based chemotherapy. *Annals of Oncology*, **2013**, 24, 2349-53	10.3	25
324	Intratumoral heterogeneity: Role of differentiation in a potentially lethal phenotype of testicular cancer. *Cancer*, **2016**, 122, 1836-43	6.4	25
323	Circulating Tumor DNA-Defined Minimal Residual Disease in Solid Tumors: Opportunities to Accelerate the Development of Adjuvant Therapies. *Journal of Clinical Oncology*, **2018**, JCO2018789032	2.2	25
322	Current and Future Approaches to Target the Epidermal Growth Factor Receptor and Its Downstream Signaling in Metastatic Colorectal Cancer. *Clinical Colorectal Cancer*, **2015**, 14, 203-18	3.8	24
321	Combination of nivolumab (nivo) + ipilimumab (ipi) in the treatment of patients (pts) with deficient DNA mismatch repair (dMMR)/high microsatellite instability (MSI-H) metastatic colorectal cancer (mCRC): CheckMate 142 study.. *Journal of Clinical Oncology*, **2017**, 35, 3531-3531	2.2	24
320	A NOTCH1 gene copy number gain is a prognostic indicator of worse survival and a predictive biomarker to a Notch1 targeting antibody in colorectal cancer. *International Journal of Cancer*, **2016** , 138, 195-205	7.5	24
319	Modeling of Patient-Derived Xenografts in Colorectal Cancer. *Molecular Cancer Therapeutics*, **2017**, 16, 1435-1442	6.1	23
318	Colorectal premalignancy is associated with consensus molecular subtypes 1 and 2. *Annals of Oncology*, **2018**, 29, 2061-2067	10.3	23
317	Circulating tumor DNA (ctDNA) utilizing a high-sensitivity panel to detect minimal residual disease post liver hepatectomy and predict disease recurrence.. *Journal of Clinical Oncology*, **2017**, 35, 3522-3522	2.2	23
316	Can Microsatellite Status of Colorectal Cancer Be Reliably Assessed after Neoadjuvant Therapy?. *Clinical Cancer Research*, **2017**, 23, 5246-5254	12.9	22
315	Nivolumab in the treatment of microsatellite instability high metastatic colorectal cancer. *Future Oncology*, **2018**, 14, 1869-1874	3.6	22
314	Nivolumab (NIVO) + low-dose ipilimumab (IPI) in previously treated patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Long-term follow-up.. *Journal of Clinical Oncology*, **2019**, 37, 635-635	2.2	22
313	Encorafenib plus cetuximab with or without binimetinib for BRAF V600E metastatic colorectal cancer: Updated survival results from a randomized, three-arm, phase III study versus choice of either irinotecan or FOLFIRI plus cetuximab (BEACON CRC).. *Journal of Clinical Oncology*, **2020**, 38, 4001-4001	2.2	22
312	Detection of somatic mutations in cell-free DNA in plasma and correlation with overall survival in patients with solid tumors. *Oncotarget*, **2018**, 9, 10259-10271	3.3	22
311	Study of Preanalytic and Analytic Variables for Clinical Next-Generation Sequencing of Circulating Cell-Free Nucleic Acid. *Journal of Molecular Diagnostics*, **2017**, 19, 514-524	5.1	21

310	Clinical utility of circulating cell-free DNA in advanced colorectal cancer. *PLoS ONE*, **2017**, 12, e0183949	3.7	21
309	First-in-human trial of the PI3K□selective inhibitor SAR260301 in patients with advanced solid tumors. *Cancer*, **2018**, 124, 315-324	6.4	21
308	Prognostic Implications of Mucinous Differentiation in Metastatic Colorectal Carcinoma Can Be Explained by Distinct Molecular and Clinicopathologic Characteristics. *Clinical Colorectal Cancer*, **2018**, 17, e699-e709	3.8	21
307	Current and Future Horizons of Patient-Derived Xenograft Models in Colorectal Cancer Translational Research. *Cancers*, **2019**, 11,	6.6	20
306	Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline Summary From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical Oncology. *Journal of Oncology Practice*, **2017**, 13, 333-337	3.1	20
305	A New Surveillance Algorithm After Resection of Colorectal Liver Metastases Based on Changes in Recurrence Risk and RAS Mutation Status. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2020**, 18, 1500-1508	7.3	20
304	APC and PIK3CA Mutational Cooperativity Predicts Pathologic Response and Survival in Patients Undergoing Resection for Colorectal Liver Metastases. *Annals of Surgery*, **2020**, 272, 1080-1085	7.8	20
303	Consensus statement on essential patient characteristics in systemic treatment trials for metastatic colorectal cancer: Supported by the ARCAD Group. *European Journal of Cancer*, **2018**, 100, 35-45	7.5	20
302	Molecular Biomarkers for the Evaluation of Colorectal Cancer. *American Journal of Clinical Pathology*, **2017**, 147, 221-260	1.9	19
301	Ongoing and future directions in the management of metastatic colorectal cancer: Update on clinical trials. *Journal of Surgical Oncology*, **2019**, 119, 642-652	2.8	19
300	First-in-human trial of multikinase VEGF inhibitor regorafenib and anti-EGFR antibody cetuximab in advanced cancer patients. *JCI Insight*, **2017**, 2,	9.9	19
299	Proteomic Features of Colorectal Cancer Identify Tumor Subtypes Independent of Oncogenic Mutations and Independently Predict Relapse-Free Survival. *Annals of Surgical Oncology*, **2017**, 24, 4051-4058	3.1	19
298	New therapies and insights into the changing landscape of colorectal cancer. *Nature Reviews Gastroenterology and Hepatology*, **2019**, 16, 79-80	24.2	19
297	Targeting -Mutant Colorectal Cancer: Progress in Combination Strategies. *Cancer Discovery*, **2017**, 7, 558-560	24.4	18
296	Modifying Practices in GI Oncology in the Face of COVID-19: Recommendations From Expert Oncologists on Minimizing Patient Risk. *JCO Oncology Practice*, **2020**, 16, 383-388	2.3	18
295	Current companion diagnostics in advanced colorectal cancer; getting a bigger and better piece of the pie. *Journal of Gastrointestinal Oncology*, **2017**, 8, 199-212	2.8	18
294	Sotorasib for previously treated colorectal cancers with KRAS mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial.. *Lancet Oncology, The*, **2021**,	21.7	18
293	Nivolumab in patients with DNA mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) metastatic colorectal cancer (mCRC): Long-term survival according to prior line of treatment from CheckMate-142.. *Journal of Clinical Oncology*, **2018**, 36, 554-554	2.2	18

292	Adjuvant chemotherapy for stage II colon cancer. *Oncology*, **2008**, 22, 260-70; discussion 270, 273, 275	1.8	18
291	Phase II study of nab-paclitaxel in refractory small bowel adenocarcinoma and CpG island methylator phenotype (CIMP)-high colorectal cancer. *Annals of Oncology*, **2018**, 29, 139-144	10.3	17
290	Impact of RAS Mutations in Metastatic Colorectal Cancer After Potentially Curative Resection: Does Site of Metastases Matter?. *Annals of Surgical Oncology*, **2018**, 25, 179-187	3.1	17
289	Joint prognostic effect of obesity and chronic systemic inflammation in patients with metastatic colorectal cancer. *Cancer*, **2015**, 121, 2968-75	6.4	17
288	Preoperative radiation therapy with concurrent capecitabine, bevacizumab, and erlotinib for rectal cancer: a phase 1 trial. *International Journal of Radiation Oncology Biology Physics*, **2014**, 88, 301-5	4	17
287	Comparison of prognostic genomic predictors in colorectal cancer. *PLoS ONE*, **2013**, 8, e60778	3.7	17
286	Circulating inflammation signature predicts overall survival and relapse-free survival in metastatic colorectal cancer. *British Journal of Cancer*, **2019**, 120, 340-345	8.7	17
285	Pathological Tumor Response Following Immune Checkpoint Blockade for Deficient Mismatch Repair Advanced Colorectal Cancer. *Journal of the National Cancer Institute*, **2021**, 113, 208-211	9.7	17
284	Comparison of early radiological predictors of outcome in patients with colorectal cancer with unresectable hepatic metastases treated with bevacizumab. *Gut*, **2018**, 67, 1095-1102	19.2	16
283	Loss of muscle mass during preoperative chemotherapy as a prognosticator for poor survival in patients with colorectal liver metastases. *Surgery*, **2019**, 165, 329-336	3.6	16
282	Embryonic origin of primary colon cancer predicts survival in patients undergoing ablation for colorectal liver metastases. *European Journal of Surgical Oncology*, **2017**, 43, 1040-1049	3.6	15
281	The Addition of Bevacizumab to Oxaliplatin-Based Chemotherapy: Impact Upon Hepatic Sinusoidal Injury and Thrombocytopenia. *Journal of the National Cancer Institute*, **2018**, 110, 888-894	9.7	15
280	Platelet Metabolism and Other Targeted Drugs; Potential Impact on Immunotherapy. *Frontiers in Oncology*, **2018**, 8, 107	5.3	15
279	Predictors of health-related quality of life and association with survival may identify colorectal cancer patients at high risk of poor prognosis. *Quality of Life Research*, **2017**, 26, 319-330	3.7	15
278	Survival benefit associated with surgical oophorectomy in patients with colorectal cancer metastatic to the ovary. *Clinical Colorectal Cancer*, **2012**, 11, 191-4	3.8	15
277	Systematic survey of therapeutic trials for metastatic colorectal cancer: room for improvement in the critical pathway. *Journal of Clinical Oncology*, **2008**, 26, 2000-5	2.2	15
276	RAS Mutation is Associated with Unsalvageable Recurrence Following Hepatectomy for Colorectal Cancer Liver Metastases. *Annals of Surgical Oncology*, **2018**, 25, 2457-2466	3.1	15
275	Untying the gordion knot of targeting MET in cancer. *Cancer Treatment Reviews*, **2018**, 66, 95-103	14.4	14

274	Signet ring cell colorectal cancer: genomic insights into a rare subpopulation of colorectal adenocarcinoma. *British Journal of Cancer*, **2019**, 121, 505-510	8.7	14
273	A multicenter, multinational analysis of mitomycin C in refractory metastatic colorectal cancer. *European Journal of Cancer*, **2012**, 48, 820-6	7.5	14
272	Phase 1-2 trial of the BRAF inhibitor dabrafenib (D) plus MEK inhibitor trametinib (T) in BRAF V600 mutant colorectal cancer (CRC): Updated efficacy and biomarker analysis.. *Journal of Clinical Oncology*, **2014**, 32, 3517-3517	2.2	14
271	Validation of Amplification as a Predictive Biomarker for Anti-Epidermal Growth Factor Receptor Antibody Therapy in Metastatic Colorectal Cancer.. *JCO Precision Oncology*, **2019**, 3, 1-13	3.6	14
270	Triple blockade of EGFR, MEK and PD-L1 has antitumor activity in colorectal cancer models with constitutive activation of MAPK signaling and PD-L1 overexpression. *Journal of Experimental and Clinical Cancer Research*, **2019**, 38, 492	12.8	14
269	DNA Sequencing of Small Bowel Adenocarcinomas Identifies Targetable Recurrent Mutations in the ERBB2 Signaling Pathway. *Clinical Cancer Research*, **2019**, 25, 641-651	12.9	14
268	ARID1A Mutation May Define an Immunologically Active Subgroup in Patients with Microsatellite Stable Colorectal Cancer. *Clinical Cancer Research*, **2021**, 27, 1663-1670	12.9	14
267	Preoperative radiation dose escalation for rectal cancer using a concomitant boost strategy improves tumor downstaging without increasing toxicity: A matched-pair analysis. *Advances in Radiation Oncology*, **2017**, 2, 455-464	3.3	13
266	Bioactive lipid metabolism in platelet "first responder" and cancer biology. *Cancer and Metastasis Reviews*, **2018**, 37, 439-454	9.6	13
265	Hidden biases in an observational study of bevacizumab beyond progression. *Journal of Clinical Oncology*, **2009**, 27, 1732-3; author reply 1733	2.2	13
264	Association of primary (1□) site and molecular features with progression-free survival (PFS) and overall survival (OS) of metastatic colorectal cancer (mCRC) after anti-epidermal growth factor receptor (⊟EGFR) therapy.. *Journal of Clinical Oncology*, **2016**, 34, 3506-3506	2.2	13
263	Oncologic and Functional Hazards of Obesity Among Patients With Locally Advanced Rectal Cancer Following Neoadjuvant Chemoradiation Therapy. *American Journal of Clinical Oncology: Cancer Clinical Trials*, **2017**, 40, 277-282	2.7	12
262	Population-based Screening for in Metastatic Colorectal Cancer Reveals Increased Prevalence and Poor Prognosis. *Clinical Cancer Research*, **2020**, 26, 4599-4605	12.9	12
261	Impact of Prior Hepatectomy History on Local Tumor Progression after Percutaneous Ablation of Colorectal Liver Metastases. *Journal of Vascular and Interventional Radiology*, **2018**, 29, 395-403.e1	2.4	12
260	Genetic profiling as a clinical tool in advanced parathyroid carcinoma. *Journal of Cancer Research and Clinical Oncology*, **2019**, 145, 1977-1986	4.9	12
259	Cancer in silico drug discovery: a systems biology tool for identifying candidate drugs to target specific molecular tumor subtypes. *Molecular Cancer Therapeutics*, **2014**, 13, 3230-40	6.1	12
258	Phase 1B study of vemurafenib in combination with irinotecan and cetuximab in patients with BRAF-mutated advanced cancers and metastatic colorectal cancer.. *Journal of Clinical Oncology*, **2014**, 32, 3516-3516	2.2	12
257	Updated results of the BEACON CRC safety lead-in: Encorafenib (ENCO) + binimetinib (BINI) + cetuximab (CETUX) for BRAFV600E-mutant metastatic colorectal cancer (mCRC).. *Journal of Clinical Oncology*, **2019**, 37, 688-688	2.2	12

256	Antitumor effects of cyclin dependent kinase 9 inhibition in esophageal adenocarcinoma. *Oncotarget*, **2017**, 8, 28696-28710	3.3	12
255	A feasibility study of returning clinically actionable somatic genomic alterations identified in a research laboratory. *Oncotarget*, **2017**, 8, 41806-41814	3.3	12
254	Planned Treatment of Advanced Metastatic Disease with Completion Ablation After Hepatic Resection. *Journal of Gastrointestinal Surgery*, **2017**, 21, 628-635	3.3	11
253	BRAF V600 mutant colorectal cancer (CRC) expansion cohort from the phase I/II clinical trial of BRAF inhibitor dabrafenib (GSK2118436) plus MEK inhibitor trametinib (GSK1120212).. *Journal of Clinical Oncology*, **2012**, 30, 3528-3528	2.2	11
252	Targeting SRC and epidermal growth factor receptor in colorectal cancer: rationale and progress into the clinic. *Gastrointestinal Cancer Research: GCR*, **2007**, 1, S37-41		11
251	International Harmonization of Provisional Diagnostic Criteria for -Amplified Metastatic Colorectal Cancer Allowing for Screening by Next-Generation Sequencing Panel.. *JCO Precision Oncology*, **2020**, 4, 6-19	3.6	11
250	Efficacy, Safety, and Biomarker Analysis of Combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) Blockade in Advanced Malignant Peritoneal Mesothelioma. *Cancer Discovery*, **2021**, 11, 2738-2747	24.4	11
249	Development and Validation of a Gene Signature Classifier for Consensus Molecular Subtyping of Colorectal Carcinoma in a CLIA-Certified Setting. *Clinical Cancer Research*, **2021**, 27, 120-130	12.9	11
248	Prognostic impact of perihepatic lymph node metastases in patients with resectable colorectal liver metastases. *British Journal of Surgery*, **2018**, 105, 1200-1209	5.3	10
247	CTC analysis: an update on technological progress. *Translational Research*, **2019**, 212, 14-25	11	10
246	Individualized Treatment Sequencing Selection Contributes to Optimized Survival in Patients with Rectal Cancer and Synchronous Liver Metastases. *Annals of Surgical Oncology*, **2017**, 24, 3857-3864	3.1	10
245	Src activity is modulated by oxaliplatin and correlates with outcomes after hepatectomy for metastatic colorectal cancer. *BMC Cancer*, **2014**, 14, 660	4.8	10
244	M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF-in patients with heavily pretreated CRC: Preliminary results from a phase I trial.. *Journal of Clinical Oncology*, **2018**, 36, 764-764	2.2	10
243	PI-3-Kinase inhibitors in colorectal cancer. *Current Cancer Drug Targets*, **2011**, 11, 190-8	2.8	10
242	Contour prognostic model for predicting survival after resection of colorectal liver metastases: development and multicentre validation study using largest diameter and number of metastases with RAS mutation status. *British Journal of Surgery*, **2021**, 108, 968-975	5.3	10
241	Alteration of FBXW7 is Associated with Worse Survival in Patients Undergoing Resection of Colorectal Liver Metastases. *Journal of Gastrointestinal Surgery*, **2021**, 25, 186-194	3.3	10
240	Convergence of nanotechnology and cancer prevention: are we there yet?. *Cancer Prevention Research*, **2014**, 7, 973-92	3.2	9
239	Emerging drugs for colorectal cancer. *Expert Opinion on Emerging Drugs*, **2008**, 13, 629-42	3.7	9

238	Phase Ib study of vemurafenib in combination with irinotecan and cetuximab in patients with BRAF-mutated metastatic colorectal cancer and advanced cancers.. *Journal of Clinical Oncology*, **2015**, 33, 3511-3511	2.2	9
237	Identification of biomarkers of immune checkpoint blockade efficacy in recurrent or refractory solid tumor malignancies. *Oncotarget*, **2020**, 11, 600-618	3.3	9
236	Colon Cancer in Patients Under 25 Years Old: A Different Disease?. *Journal of the American College of Surgeons*, **2020**, 230, 648-656	4.4	8
235	Evaluating for Pseudoprogression in Colorectal and Pancreatic Tumors Treated With Immunotherapy. *Journal of Immunotherapy*, **2018**, 41, 284-291	5	8
234	Tumor Microenvironment in Gene Signatures: Critical Biology or Confounding Noise?. *Clinical Cancer Research*, **2016**, 22, 3989-91	12.9	8
233	BEACON CRC study safety lead-in: Assessment of the BRAF inhibitor encorafenib + MEK inhibitor binimetinib + anti□epidermal growth factor receptor antibody cetuximab for BRAFV600E metastatic colorectal cancer. *Annals of Oncology*, **2018**, 29, v109	10.3	8
232	Global differences in the prevalence of the CpG island methylator phenotype of colorectal cancer. *BMC Cancer*, **2019**, 19, 964	4.8	8
231	MIIP haploinsufficiency induces chromosomal instability and promotes tumour progression in colorectal cancer. *Journal of Pathology*, **2017**, 241, 67-79	9.4	8
230	Barriers to Integrating Gene Profiling for Stage II Colon Cancer. *Clinical Cancer Research*, **2009**, 15, 7451-7452	11.5	8
229	Mutation and copy number discordance in primary versus metastatic colorectal cancer (mCRC).. *Journal of Clinical Oncology*, **2014**, 32, 3509-3509	2.2	8
228	Genomic analysis of exceptional responder to regorafenib in treatment-refractory metastatic rectal cancer: a case report and review of the literature. *Oncotarget*, **2017**, 8, 57882-57888	3.3	8
227	AMPK□1 confers survival advantage of colorectal cancer cells under metabolic stress by promoting redox balance through the regulation of glutathione reductase phosphorylation. *Oncogene*, **2020**, 39, 637-650	9.2	8
226	Integrated safety summary for trifluridine/tipiracil (TAS-102). *Anti-Cancer Drugs*, **2018**, 29, 89-96	2.4	8
225	Prognostic factors after resection of colorectal liver metastases following preoperative second-line chemotherapy: Impact of RAS mutations. *European Journal of Surgical Oncology*, **2016**, 42, 1378-84	3.6	7
224	Targeting () Amplification Identified by Next-Generation Sequencing in Patients With Advanced or Metastatic Solid Tumors Beyond Conventional Indications. *JCO Precision Oncology*, **2019**, 3,	3.6	7
223	Preliminary results from a phase II study of infusional 5-FU, leucovorin, and irinotecan (FOLFIRI) plus bevacizumab as first-line treatment for metastatic colorectal cancer (mCRC). *Journal of Clinical Oncology*, **2006**, 24, 3579-3579	2.2	7
222	Pharmacodynamic and efficacy analysis of the BRAF inhibitor dabrafenib (GSK436) in combination with the MEK inhibitor trametinib (GSK212) in patients with BRAFV600 mutant colorectal cancer (CRC).. *Journal of Clinical Oncology*, **2013**, 31, 3507-3507	2.2	7
221	Anti-EGFR resistant clones decay exponentially after progression: Implications for anti-EGFR rechallenge.. *Journal of Clinical Oncology*, **2018**, 36, 3511-3511	2.2	7

220	Distinct impacts of KRAS, NRAS and BRAF mutations on survival of patients with metastatic colorectal cancer.. *Journal of Clinical Oncology*, **2018**, 36, 3513-3513	2.2	7
219	Comprehensive Clinical and Molecular Characterization of -Mutant Colorectal Cancer. *JCO Precision Oncology*, **2021**, 5,	3.6	7
218	Nivolumab □ ipilimumab treatment (Tx) efficacy, safety, and biomarkers in patients (Pts) with metastatic colorectal cancer (mCRC) with and without high microsatellite instability (MSI-H): results from the CheckMate-142 study. *Annals of Oncology*, **2016**, 27, vi158	10.3	7
217	A novel patient-derived orthotopic xenograft model of esophageal adenocarcinoma provides a platform for translational discoveries. *DMM Disease Models and Mechanisms*, **2019**, 12,	4.1	7
216	Improved Survival over Time After Resection of Colorectal Liver Metastases and Clinical Impact of Multigene Alteration Testing in Patients with Metastatic Colorectal Cancer. *Journal of Gastrointestinal Surgery*, **2021**, 1	3.3	7
215	Real-Time Interrogation of Aspirin Reactivity, Biochemistry, and Biodistribution by Hyperpolarized Magnetic Resonance Spectroscopy. *Angewandte Chemie - International Edition*, **2019**, 58, 4179-4183	16.4	6
214	Use of a Targeted Exome Next-Generation Sequencing Panel Offers Therapeutic Opportunity and Clinical Benefit in a Subset of Patients With Advanced Cancers. *JCO Precision Oncology*, **2019**, 3,	3.6	6
213	Targeting CDK9 and MCL-1 by a new CDK9/p-TEFb inhibitor with and without 5-fluorouracil in esophageal adenocarcinoma. *Therapeutic Advances in Medical Oncology*, **2019**, 11, 1758835919864850	5.4	6
212	Early-Onset Signet-Ring Cell Adenocarcinoma of the Colon: A Case Report and Review of the Literature. *Case Reports in Oncological Medicine*, **2017**, 2017, 2832180	0.9	6
211	Outcomes in 144 patients with colorectal cancer treated in a phase I clinic: the MD Anderson Cancer Center experience. *Clinical Colorectal Cancer*, **2012**, 11, 297-303	3.8	6
210	Second-line chemotherapy use in metastatic colon cancer varies by disease responsiveness. *Clinical Colorectal Cancer*, **2008**, 7, 55-9	3.8	6
209	Pulmonary arteriovenous fistula in a patient with renal cell carcinoma. *European Respiratory Journal* , **2007**, 29, 813-5	13.6	6
208	RETRIEVAL OF AEROSOL OPTICAL THICKNESS BY MEANS OF THE LEAST-MEDIAN-SQUARES ROBUST ALGORITHM. *Journal of Aerosol Science*, **1999**, 30, 805-817	4.3	6
207	"Right drug for the right patient": hurdles and the path forward in colorectal cancer. *American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting*, **2013**,	7.1	6
206	A phase II and co-clinical study of an AKT inhibitor in patients (pts) with biomarker-enriched, previously treated metastatic colorectal cancer (mCRC).. *Journal of Clinical Oncology*, **2016**, 34, 3563-3563	2.2	6
205	Not all RAS mutations created equal: Functional and clinical characterization of 80 different KRAS and NRAS mutations.. *Journal of Clinical Oncology*, **2017**, 35, 3589-3589	2.2	6
204	Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) study (NRG- GI004/SWOG-S1610): A randomized phase III study of mFOLFOX6/bevacizumab combination chemotherapy with or without atezolizumab or atezolizumab monotherapy in the first-line treatment of patients with deficient DNA mismatch repair (dMMR) metastatic colorectal cancer.. *Journal of Clinical Oncology*, 2018, 36, TPS3615-TPS3615	2.2	6
203	A randomized phase II study of trastuzumab and pertuzumab (TP) compared to cetuximab and irinotecan (CETIRI) in advanced/metastatic colorectal cancer (mCRC) with HER2 amplification: S1613.. *Journal of Clinical Oncology*, **2018**, 36, TPS3620-TPS3620	2.2	6

202	Targeting cyclin-dependent kinase 9 by a novel inhibitor enhances radiosensitization and identifies Axl as a novel downstream target in esophageal adenocarcinoma. *Oncotarget*, **2019**, 10, 4703-4718	3.3	6
201	Expanded Low Allele Frequency and V600E Testing in Metastatic Colorectal Cancer as Predictive Biomarkers for Cetuximab in the Randomized CO.17 Trial. *Clinical Cancer Research*, **2021**, 27, 52-59	12.9	6
200	Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidatesfor targeted treatment. *Nature Communications*, **2021**, 12, 5086	17.4	6
199	Identification of Actionable Fusions as an Anti-EGFR Resistance Mechanism Using a Circulating Tumor DNA Assay. *JCO Precision Oncology*, **2019**, 3,	3.6	5
198	Non-invasive genotyping of metastatic colorectal cancer using circulating cell free DNA. *Cancer Genetics*, **2019**, 237, 82-89	2.3	5
197	Medical Oncologists' Perspectives on How the Results of the IDEA Collaboration Impact the Adjuvant Treatment of Stage III Colon Cancer. *Oncologist*, **2020**, 25, 229-234	5.7	5
196	Residual tumor thickness at the tumor-normal tissue interface predicts the recurrence-free survival in patients with liver metastasis of breast cancer. *Annals of Diagnostic Pathology*, **2014**, 18, 266-70	2.2	5
195	Activity of EGFR inhibition in atypical (non-V600E) BRAF-mutated metastatic colorectal cancer.. *Journal of Clinical Oncology*, **2019**, 37, 596-596	2.2	5
194	Vestigial-like 1 is a shared targetable cancer-placenta antigen expressed by pancreatic and basal-like breast cancers. *Nature Communications*, **2020**, 11, 5332	17.4	5
193	Applying Precision to the Management of BRAF-Mutant Metastatic Colorectal Cancer. *Targeted Oncology*, **2020**, 15, 567-577	5	5
192	Atypical, Non-V600 BRAF Mutations as a Potential Mechanism of Resistance to EGFR Inhibition in Metastatic Colorectal Cancer. *JCO Precision Oncology*, **2019**, 3,	3.6	5
191	Sex Representation in Clinical Trials Associated with FDA Cancer Drug Approvals Differs Between Solid and Hematologic Malignancies. *Oncologist*, **2021**, 26, 107-114	5.7	5
190	Sequential Administration of XPO1 and ATR Inhibitors Enhances Therapeutic Response in TP53-mutated Colorectal Cancer. *Gastroenterology*, **2021**, 161, 196-210	13.3	5
189	Combining Neratinib with CDK4/6, mTOR, and MEK Inhibitors in Models of HER2-positive Cancer. *Clinical Cancer Research*, **2021**, 27, 1681-1694	12.9	5
188	Patient-derived micro-organospheres enable clinical precision oncology.. *Cell Stem Cell*, **2022**,	18	5
187	KRAS mutation in colorectal cancer metastases after adjuvant FOLFOX for the primary. *British Journal of Cancer*, **2012**, 107, 1442-3; author reply 1444	8.7	4
186	Abstract 2603: Exploratory analysis of Janus kinase 1 (JAK1) loss-of-function (LoF) mutations in patients with DNA mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) metastatic colorectal cancer (mCRC) treated with nivolumab + ipilimumab in CheckMate-142 **2018**,		4
185	Prevalence of incidental actionable germline mutations in 1,000 advanced cancer patients on a prospective somatic genomic profiling program.. *Journal of Clinical Oncology*, **2015**, 33, 1510-1510	2.2	4

184	First-in-human phase I trial of the PI3Kb-selective inhibitor SAR260301 in patients with advanced solid tumors (NCT01673737).. *Journal of Clinical Oncology*, **2015**, 33, 2564-2564	2.2	4
183	Concordance of DNA mismatch repair deficient (dMMR)/microsatellite instability (MSI) assessment by local and central testing in patients with metastatic CRC (mCRC) receiving nivolumab (nivo) in CheckMate 142 study.. *Journal of Clinical Oncology*, **2017**, 35, 3548-3548	2.2	4
182	LUNA: A randomized phase II trial of liver resection plus chemotherapy or chemotherapy alone in patients with unresectable lung and resectable liver metastases from colorectal adenocarcinoma.. *Journal of Clinical Oncology*, **2017**, 35, TPS3625-TPS3625	2.2	4
181	Actionable fusions in colorectal cancer using a cell-free circulating tumor DNA (ctDNA) assay.. *Journal of Clinical Oncology*, **2018**, 36, 3507-3507	2.2	4
180	International harmonization of diagnostic criteria for HER2-amplified metastatic colorectal cancer and application of targeted next-generation sequencing panel as a diagnostic method.. *Journal of Clinical Oncology*, **2018**, 36, 3594-3594	2.2	4
179	Association of PIK3CA mutations (mut) with immune engagement and clinical benefit from immunotherapy in microsatellite stable (MSS) colorectal cancer (CRC) patients (pts).. *Journal of Clinical Oncology*, **2019**, 37, 3604-3604	2.2	4
178	Sulindac plus a phospholipid is effective for polyp reduction and safer than sulindac alone in a mouse model of colorectal cancer development. *BMC Cancer*, **2020**, 20, 871	4.8	4
177	Clinical and Functional Characterization of Atypical / Mutations in Metastatic Colorectal Cancer. *Clinical Cancer Research*, **2021**, 27, 4587-4598	12.9	4
176	Expanded analysis of secondary germline findings from matched tumor/normal sequencing identifies additional clinically significant mutations. *JCO Precision Oncology*, **2019**, 3,	3.6	4
175	The BE GONE trial study protocol: a randomized crossover dietary intervention of dry beans targeting the gut microbiome of overweight and obese patients with a history of colorectal polyps or cancer. *BMC Cancer*, **2019**, 19, 1233	4.8	4
174	Platelets: First Responders in Cancer Progression and Metastasis **2017**, 1111-1132		3
173	Development and Application of Duplex Sequencing Strategy for Cell-Free DNA-Based Longitudinal Monitoring of Stage IV Colorectal Cancer. *Journal of Molecular Diagnostics*, **2019**, 21, 994-1009	5.1	3
172	Liquid biopsy, a paradigm shift in oncology: what interventional radiologists should know. *European Radiology*, **2020**, 30, 4496-4503	8	3
171	Phase I studies of vorinostat with ixazomib or pazopanib imply a role of antiangiogenesis-based therapy for TP53 mutant malignancies. *Scientific Reports*, **2020**, 10, 3080	4.9	3
170	Accelerating Therapeutic Development through Innovative Trial Design in Colorectal Cancer. *Current Treatment Options in Oncology*, **2018**, 19, 11	5.4	3
169	Systemic cytotoxic and biologic therapies for colorectal cancer liver metastases: expert consensus statement. *Hpb*, **2013**, 15, 116-8	3.8	3
168	Why a One Size Fits All Approach to Might Not Fit Colorectal Cancer. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2017**, 15, 545-547	7.3	3
167	Heterogeneity of acquired KRAS and EGFR mutations in colorectal cancer patients treated with anti-EGFR monoclonal antibodies.. *Journal of Clinical Oncology*, **2013**, 31, 3512-3512	2.2	3

166	BEACON CRC (binimetinib [BINI], encorafenib [ENCO], and cetuximab [CTX] combined to treat BRAF-mutant metastatic colorectal cancer [mCRC]): A multicenter, randomized, open-label, three-arm phase III study of ENCO plus CTX plus or minus BINI vs irinotecan (IRI)/CTX or infusional 5-fluorouracil/folinic acid/IRI (FOLFIRI)/CTX with a safety lead-in of ENCO + BINI + CTX in patients (Pts) with BRAFV600E mCRC.. *Journal of Clinical Oncology*, **2017**, 35, TPS3622-TPS3622	2.2	3
165	The characteristics of ARID1A mutations in colorectal cancer.. *Journal of Clinical Oncology*, **2018**, 36, 3595-3595	2.2	3
164	Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) study (NRG- GI004/SWOG-S1610): A randomized phase III study of mFOLFOX6/bevacizumab combination chemotherapy with or without atezolizumab or atezolizumab monotherapy in the first-line treatment of patients (pts) with deficient DNA mismatch repair (dMMR) metastatic colorectal cancer (mCRC).. *Journal of*	2.2	3
163	Platelet microparticles: small payloads with profound effects on tumor growth. *Non-coding RNA Investigation*, **2017**, 1,	0.6	3
162	Relative Abundance of SARS-CoV-2 Entry Genes in the Enterocytes of the Lower Gastrointestinal Tract		3
161	Epidemiology and Molecular-Pathologic Characteristics of CpG Island Methylator Phenotype (CIMP) in Colorectal Cancer. *Clinical Colorectal Cancer*, **2021**, 20, 137-147.e1	3.8	3
160	Pilot Clinical Trial of Perioperative Durvalumab and Tremelimumab in the Treatment of Resectable Colorectal Cancer Liver Metastases. *Clinical Cancer Research*, **2021**, 27, 3039-3049	12.9	3
159	Phase II trial of bintrafusp alfa in patients with metastatic MSI-H cancers following progression on immunotherapy.. *Journal of Clinical Oncology*, **2021**, 39, 79-79	2.2	3
158	SO-27 Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142. *Annals of Oncology*, **2021**, 32, S213-S214	10.3	3
157	Going with the Flow: The Promise of Plasma-Only Circulating Tumor DNA Assays. *Clinical Cancer Research*, **2021**, 27, 5449-5451	12.9	3
156	Genomic Sequencing and Insight into Clinical Heterogeneity and Prognostic Pathway Genes in Patients with Metastatic Colorectal Cancer. *Journal of the American College of Surgeons*, **2021**, 233, 272-284.e13	4.4	3
155	Chromatin Remodeling of Colorectal Cancer Liver Metastasis is Mediated by an HGF-PU.1-DPP4 Axis. *Advanced Science*, **2021**, 8, e2004673	13.6	3
154	Cytotoxic chemotherapy for advanced colorectal cancer. Recent advances in management. *Oncology*, **2005**, 19, 11-7	1.8	3
153	FOLFOXIRI Versus Doublet Regimens in Right-Sided Metastatic Colorectal Cancer: Focus on Subsequent Therapies and Impact on Overall Survival. *Clinical Colorectal Cancer*, **2020**, 19, 248-255.e6	3.8	2
152	LBA-7 Encorafenib plus cetuximab with or without binimetinib for BRAFV600E metastatic colorectal cancer (mCRC): Relationship between carcinoembryonic antigen (CEA) and clinical outcomes from BEACON CRC. *Annals of Oncology*, **2020**, 31, S243	10.3	2
151	1 Feasibility of large-scale genomic testing to facilitate enrollment on genomically-matched clinical trials. *European Journal of Cancer*, **2014**, 50, 3	7.5	2
150	Commentary: practice patterns and potential impact on quality measures for a practicing physician. *Journal of Oncology Practice*, **2009**, 5, 233-5	3.1	2
149	A phase II study of UFT with leucovorin administered as a twice daily schedule in the treatment of patients with metastatic colorectal cancer. *British Journal of Cancer*, **2008**, 99, 722-6	8.7	2

148	Of vascular defense, hemostasis, cancer, and platelet biology: an evolutionary perspective.. *Cancer and Metastasis Reviews*, **2022**, 41, 147	9.6	2
147	Cell membrane-anchored and tumor-targeted IL-12 (attIL12)-T cell therapy for eliminating large and heterogeneous solid tumors. **2022**, 10,		2
146	Abstract 8: Global and targeted metabolomic profiling of colorectal cancer progression **2016**,		2
145	Phase II study of infusional 5-fluorouracil, leucovorin, and irinotecan (FOLFIRI) plus bevacizumab as first-line treatment for metastatic colorectal cancer. *Journal of Clinical Oncology*, **2007**, 25, 4089-4089	2.2	2
144	The use of 5-fluorouracil and oxaliplatin (FOLFOX) for colorectal cancer is associated with the development of splenomegaly and thrombocytopenia. *Journal of Clinical Oncology*, **2008**, 26, 4102-4102	2.2	2
143	Differences in sites of metastatic disease and outcomes observed in patients with BRAF mutant colorectal cancers.. *Journal of Clinical Oncology*, **2010**, 28, 3592-3592	2.2	2
142	Exploratory analysis of adjuvant chemotherapy effects after preoperative chemoradiotherapy and radical resection for rectal cancer.. *Journal of Clinical Oncology*, **2012**, 30, 557-557	2.2	2
141	Genomic classifier (ColoPrint) to predict outcome and chemotherapy benefit in stage II and III colon cancer patients.. *Journal of Clinical Oncology*, **2013**, 31, 3612-3612	2.2	2
140	Genomic classifiers (ColoPrint/MSI-Print) predict outcome and chemotherapy benefit in stage II and III colon cancer patients.. *Journal of Clinical Oncology*, **2013**, 31, 378-378	2.2	2
139	Frequency of concurrent gene mutations and copy number alterations in circulating cell-free DNA (cfDNA) from refractory metastatic CRC patients.. *Journal of Clinical Oncology*, **2014**, 32, 11117-11117	2.2	2
138	Associations between patient (pt) colorectal cancer (CRC) tumor KRAS and BRAF mutation (mut) status and overall survival (OS).. *Journal of Clinical Oncology*, **2014**, 32, 473-473	2.2	2
137	S1406: Randomized phase II study of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (mCRC).. *Journal of Clinical Oncology*, **2015**, 33, TPS790-TPS790	2.2	2
136	Immunologic profiling of consensus molecular subtype (CMS) stratified colorectal cancer (CRC) primary and liver metastectomy specimens: Implications for immune targeting of proficient mismatch repair CRC.. *Journal of Clinical Oncology*, **2016**, 34, 3520-3520	2.2	2
135	Is the neutrophil-lymphocyte ratio (NLR) a predictive and prognostic factor in rectal cancer patients treated with neoadjuvant chemoradiation (nCRT)?. *Journal of Clinical Oncology*, **2016**, 34, 3605-3605	2.2	2
134	Circulating tumor DNA (ctDNA) as an early marker to monitor clinical benefit of regorafenib and TAS-102 in patients with metastatic colorectal cancer (mCRC).. *Journal of Clinical Oncology*, **2018**, 36, 3533-3533	2.2	2
133	Association of phosphatidylinositol 3-kinase (PI3K) pathway activation with increased immune checkpoint expression in colorectal cancer (CRC) patients.. *Journal of Clinical Oncology*, **2018**, 36, 653-653	2.2	2
132	Detection and description of ERBB2 amplification using circulating cell free tumor DNA (ctDNA) genomic analysis in metastatic colorectal cancer (mCRC).. *Journal of Clinical Oncology*, **2018**, 36, 661-661	2.2	2
131	Expanded RAS and BRAF V600 testing as predictive biomarkers for single agent cetuximab in the randomized phase III CO.17 trial.. *Journal of Clinical Oncology*, **2019**, 37, 537-537	2.2	2

130	Therapeutic vulnerabilities among KRAS G12C mutant (mut) advanced cancers based on co-alteration (co-alt) patterns.. *Journal of Clinical Oncology*, **2020**, 38, 3625-3625	2.2	2
129	Novel Therapies in Development for Metastatic Colorectal Cancer. *Gastrointestinal Cancer Research: GCR*, **2014**, 7, S2-7		2
128	Arginine methylation of EGFR: a new biomarker for predicting resistance to anti-EGFR treatment. *American Journal of Cancer Research*, **2017**, 7, 2587-2599	4.4	2
127	Population-based screening for BRAF V600E in metastatic colorectal cancer (mCRC) to reveal true prognosis.. *Journal of Clinical Oncology*, **2019**, 37, 3579-3579	2.2	2
126	Targeted Therapy in Colorectal Cancer **2008**, 101-123		2
125	Tumor cell total mRNA expression shapes the molecular and clinical phenotype of cancer		2
124	455P A meta-analysis of efficacy and safety of cetuximab with biweekly vs. weekly dosing. *Annals of Oncology*, **2020**, 31, S435	10.3	2
123	Phase II/III study of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage II colon cancer:NRG-GI005 (COBRA).. *Journal of Clinical Oncology*, **2021**, 39, TPS148-TPS148	2.2	2
122	BESPOKE study protocol: a multicentre, prospective observational study to evaluate the impact of circulating tumour DNA guided therapy on patients with colorectal cancer. *BMJ Open*, **2021**, 11, e047831	3	2
121	Implications of Intratumor Heterogeneity on Consensus Molecular Subtype (CMS) in Colorectal Cancer. *Cancers*, **2021**, 13,	6.6	2
120	Characteristics and outcomes of dementia residents in an assisted living facility **2000**, 15, 586		2
119	Impact of Circulating Tumor DNA-Based Detection of Molecular Residual Disease on the Conduct and Design of Clinical Trials for Solid Tumors.. *JCO Precision Oncology*, **2022**, 6, e2100181	3.6	2
118	Management of adverse events from the treatment of encorafenib plus cetuximab for patients with BRAF V600E-mutant metastatic colorectal cancer: insights from the BEACON CRC study.. *ESMO Open*, **2021**, 6, 100328	6	2
117	The emergence of targetable pathways in colorectal cancer.. *Clinical Advances in Hematology and Oncology*, **2021**, 19, 774-783	0.6	2
116	Overall Survival in Phase 3 Clinical Trials and the Surveillance, Epidemiology, and End Results Database in Patients With Metastatic Colorectal Cancer, 1986-2016. *JAMA Network Open*, **2022**, 5, e2213588	10.4	2
115	Integration of Whole-Genome Sequencing With Circulating Tumor DNA Analysis Captures Clonal Evolution and Tumor Heterogeneity in Non-V600 BRAF Mutant Colorectal Cancer. *Clinical Colorectal Cancer*, **2020**, 19, 132-136.e3	3.8	1
114	Challenges and strategies for identifying biomarkers for colorectal cancer. *Colorectal Cancer*, **2013**, 2, 487-489	0.8	1
113	Reply to D.J. Gallagher et al. *Journal of Clinical Oncology*, **2009**, 27, e20-e21	2.2	1

112	Presence of survivin-specific cytotoxic T-lymphocytes (CTLs) in pancreatic cancer patients, and specific killing of human pancreatic carcinoma cells in vitro by survivin-specific CTLs. *Journal of Clinical Oncology*, **2007**, 25, 3070-3070	2.2	1
111	MET overexpression as a hallmark of the epithelial-mesenchymal transition (EMT) phenotype in colorectal cancer.. *Journal of Clinical Oncology*, **2013**, 31, 334-334	2.2	1
110	Increased gene copy number and amplification of FGF2 and FGFR1 in metastatic colorectal cancer.. *Journal of Clinical Oncology*, **2013**, 31, 402-402	2.2	1
109	Impact of PI3K aberrations on efficacy of perifosine (P), x-PECT: A phase III randomized study of P plus capecitabine (PC) versus placebo plus capecitabine (C) in refractory metastatic colorectal cancer (mCRC) patients.. *Journal of Clinical Oncology*, **2014**, 32, 3606-3606	2.2	1
108	A phase I/II study of azacitidine and capecitabine/oxaliplatin (CAPOX) in refractory CIMP-high metastatic colorectal cancer.. *Journal of Clinical Oncology*, **2014**, 32, 488-488	2.2	1
107	Prospective evaluation of a 409-gene next generation sequencing platform to facilitate genotype-matched clinical trial enrollment.. *Journal of Clinical Oncology*, **2015**, 33, 3608-3608	2.2	1
106	Antibody-independent isolation and characterization of circulating tumor cells using dielectrophoresis: Fluid flow fractionation in metastatic colorectal cancer.. *Journal of Clinical Oncology*, **2016**, 34, e23023-e23023	2.2	1
105	Role of MEK inhibition in improving anti-tumor responses in xenograft models of BRAF-mutated metastatic colorectal cancer.. *Journal of Clinical Oncology*, **2016**, 34, 265-265	2.2	1
104	Prevalence of incidental germline pathogenic (PV) and likely pathogenic (LPV) variants in hereditary cancer-related genes identified in matched tumor/normal sequencing of advanced solid tumors.. *Journal of Clinical Oncology*, **2017**, 35, 1524-1524	2.2	1
103	Prognostic implications of TAMs in colorectal cancer hepatic metastases.. *Journal of Clinical Oncology*, **2017**, 35, 3574-3574	2.2	1
102	Proteomic profiling of phosphatidylinositol 3-kinase (PI3K) altered metastatic colorectal cancer (mCRC) after protein kinase B (Akt) inhibition: Insulin like growth factor 1 receptor (IGF1R) mediates adaptive resistance.. *Journal of Clinical Oncology*, **2018**, 36, 3549-3549	2.2	1
101	Circulating tumor DNA profiling to identify patients with metastatic colorectal cancer with improved overall survival following Sym004 treatment.. *Journal of Clinical Oncology*, **2018**, 36, e15577-e15577	2.2	1
100	Impact of microsatellite instability (MSI) on tumor clonal evolution in metastatic colorectal cancer (mCRC).. *Journal of Clinical Oncology*, **2018**, 36, 616-616	2.2	1
99	Serial monitoring of ctDNA to highlight mutation profiles in colorectal cancer.. *Journal of Clinical Oncology*, **2018**, 36, 641-641	2.2	1
98	Preclinical development of tumor-infiltrating lymphocyte therapy for metastatic colorectal cancer.. *Journal of Clinical Oncology*, **2018**, 36, 95-95	2.2	1
97	A priori filtering of post-operative (post-op) circulating tumor DNA (ctDNA) to predict recurrence in post-metastasectomy colorectal cancer patients (CRC pts) without knowledge of tumor genotype.. *Journal of Clinical Oncology*, **2018**, 36, 12044-12044	2.2	1
96	Rechallenge with anti-EGFR-based therapy in metastatic colorectal cancer: Impact of intervening time interval and prior anti-EGFR response.. *Journal of Clinical Oncology*, **2014**, 32, 3607-3607	2.2	1
95	Low frequency KRAS G12/13 mutations in urine cell-free (cf) DNA from patients with BRAF V600E-mutant advanced cancers.. *Journal of Clinical Oncology*, **2015**, 33, 11048-11048	2.2	1

94	Relative impact of chemotherapy with or without bevacizumab on cytokines and angiogenic factors (CAFs) in metastatic colorectal cancer.. *Journal of Clinical Oncology*, **2011**, 29, 401-401	2.2	1
93	Right Drug for the Right Patient—Hurdles and the Path Forward in Colorectal Cancer. *American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting*, **2013**, e115-e120	7.1	1
92	Patient-reported Symptom Outcomes and Microsatellite Instability in Patients With Metastatic Colorectal Cancer. *Clinical Colorectal Cancer*, **2020**, 19, 48-56.e2	3.8	1
91	Reply to S. Boutayeb et al. *JCO Oncology Practice*, **2020**, 16, 525	2.3	1
90	Refining the Use of Adjuvant Oxaliplatin in Clinical Stage II or III Rectal Adenocarcinoma. *Oncologist*, **2019**, 24, e671-e676	5.7	1
89	Utility of circulating tumor DNA in the clinical management of patients with BRAFV600E metastatic colorectal cancer.. *Journal of Clinical Oncology*, **2021**, 39, 119-119	2.2	1
88	NRG-GI004/SWOG-S1610: Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study—A randomized phase III study of atezolizumab (atezo) monotherapy versus mFOLFOX6/bevacizumab/atezo in the first-line treatment of patients (pts) with deficient DNA mismatch repair (dMMR) or microsatellite instability high (MSI-H) metastatic colorectal cancer (mCRC).. *Journal of Clinical Oncology*, **2021**, 39, TPS158-TPS158	2.2	1
87	An open-label, phase II study of patritumab deruxtecan (HER3-DXd, U3-1402) in patients (pts) with previously treated advanced/metastatic colorectal cancer (CRC).. *Journal of Clinical Oncology*, **2021**, 39, TPS157-TPS157	2.2	1
86	The Provocative Roles of Platelets in Liver Disease and Cancer. *Frontiers in Oncology*, **2021**, 11, 643815	5.3	1
85	Liquid biopsies for residual disease and recurrence.. *Med*, **2021**, 2, 1292-1313	31.7	1
84	Quality of life with encorafenib plus cetuximab with or without binimetinib treatment in patients with BRAF V600E-mutant metastatic colorectal cancer: patient-reported outcomes from BEACON CRC. *ESMO Open*, **2022**, 7, 100477	6	1
83	Can Circulating Tumor DNA in Early-Stage Colorectal Cancer Be More Than a Prognostic Biomarker?. *JAMA Oncology*, **2019**, 5, 1101-1103	13.4	0
82	Combined MEK/MDM2 inhibition demonstrates antitumor efficacy in TP53 wild-type thyroid and colorectal cancers with MAPK alterations.. *Scientific Reports*, **2022**, 12, 1248	4.9	0
81	Phase II/III study of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage II colon cancer: NRG-GI005 (COBRA).. *Journal of Clinical Oncology*, **2022**, 40, TPS233-TPS233	2.3	0
80	NRG-GI004/SWOG-S1610: Colorectal cancer metastatic dMMR immuno-therapy (COMMIT) study—A randomized phase III study of atezolizumab (atezo) monotherapy versus mFOLFOX6/bevacizumab/atezo in the first-line treatment of patients (pts) with deficient DNA mismatch repair (dMMR) or microsatellite instability high (MSI-H) metastatic colorectal cancer	2.2	0
79	A Bayesian phase I/II platform design for co-developing drug combination therapies for multiple indications. *Statistics in Medicine*, **2021**, 41, 374	2.3	0
78	Efficacy and Safety of Cetuximab Dosing (biweekly vs weekly) in Patients with KRAS Wild-type Metastatic Colorectal Cancer: A Meta-analysis.. *Oncologist*, **2022**, 27, 371-379	5.7	0
77	An analysis of research biopsy core variability from over 5000 prospectively collected core samples. *Npj Precision Oncology*, **2021**, 5, 94	9.8	0

76	Phase 1b/2 study of binimetinib (BINI) in combination with nivolumab (NIVO) or NIVO plus ipilimumab (IPI) in patients (pts) with previously treated microsatellite-stable (MSS) metastatic colorectal cancer (mCRC) with RAS mutation.. *Journal of Clinical Oncology*, **2018**, 36, TPS870-TPS870	2.2	0
75	Effect of matched therapy in metastatic colorectal cancer on progression free survival in the phase I setting.. *Journal of Clinical Oncology*, **2018**, 36, 3522-3522	2.2	0
74	A systematic review of surrogate endpoints (SEPs) for overall survival (OS) in metastatic colorectal cancer (mCRC).. *Journal of Clinical Oncology*, **2019**, 37, e18206-e18206	2.2	0
73	Population pharmacokinetics and covariate analysis of Sym004, an antibody mixture against the epidermal growth factor receptor, in subjects with metastatic colorectal cancer and other solid tumors. *Journal of Pharmacokinetics and Pharmacodynamics*, **2020**, 47, 5-18	2.7	0
72	Phase II/III study of Circulating tumOr DNA as a predictive BiomaRker in Adjuvant chemotherapy in patients with stage II colon cancer: NRG-GI005 (COBRA).. *Journal of Clinical Oncology*, **2021**, 39, TPS3622-TPS3622	2.2	0
71	Serial circulating tumor DNA (ctDNA) monitoring in metastatic colorectal cancer (mCRC) reveals dynamic profile of actionable alterations.. *Journal of Clinical Oncology*, **2021**, 39, 3572-3572	2.2	0
70	Global BRAF testing practices in metastatic colorectal cancer.. *Journal of Clinical Oncology*, **2021**, 39, 128-128	2.2	0
69	PULSE: A randomized phase II open label study of panitumumab rechallenge versus standard therapy after progression on anti-EGFR therapy in patients with RAS wild-type metastatic colorectal cancer (mCRC).. *Journal of Clinical Oncology*, **2021**, 39, TPS143-TPS143	2.2	0
68	Tumor Angiogenesis **2017**, 1-32		
67	Real-Time Interrogation of Aspirin Reactivity, Biochemistry, and Biodistribution by Hyperpolarized Magnetic Resonance Spectroscopy. *Angewandte Chemie*, **2019**, 131, 4223-4227	3.6	
66	Targeted Therapy in Solid Tumors: Colorectal Cancer **2015**, 193-204		
65	BRAF Mutations in Non-Metastatic Colorectal Cancer: Current Relevance and Future Implications. *Current Colorectal Cancer Reports*, **2015**, 11, 303-310	1	
64	Reply to N. Personeni et al. *Journal of Clinical Oncology*, **2011**, 29, 2734-2735	2.2	
63	Aggressive combined modality therapy for recurrent colorectal cancer involving the duodenum and pancreas: a report of 5 cases. *Clinical Colorectal Cancer*, **2008**, 7, 338-42	3.8	
62	The immune impact of PI3K-AKT pathway inhibition in colorectal cancer.. *Journal of Clinical Oncology*, **2022**, 40, 154-154	2.2	
61	Clinical Applications of Liquid Biopsies in Gastrointestinal Oncology. *Gastrointestinal Cancer Research: GCR*, **2014**, 7, S8-S12		
60	The establishment of a palliative care consult team in a comprehensive cancer center. *Journal of Clinical Oncology*, **2005**, 23, 8093-8093	2.2	
59	Clinical and molecular characterization of early-onset colorectal cancer patients with inflammatory bowel disease.. *Journal of Clinical Oncology*, **2018**, 36, 689-689	2.2	

58	Association of SMAD4 gene mutation with incidence of peritoneal involvement in unresectable metastatic colorectal cancer.. *Journal of Clinical Oncology*, **2018**, 36, 772-772	2.2
57	Effect of matched therapy in metastatic colorectal cancer on progression free survival in the phase I setting.. *Journal of Clinical Oncology*, **2018**, 36, 619-619	2.2
56	Predictors for detecting circulating tumor DNA (ctDNA) in metastatic colorectal cancer (mCRC).. *Journal of Clinical Oncology*, **2018**, 36, 634-634	2.2
55	Malignant peritoneal mesothelioma: Clinicopathological features, prognostic factors, and survival outcomes.. *Journal of Clinical Oncology*, **2018**, 36, 650-650	2.2
54	Consensus molecular subtypes (CMS), markers of systemic inflammation (SI) and clinicopathological parameters in colorectal cancer (CRC).. *Journal of Clinical Oncology*, **2018**, 36, e15600-e15600	2.2
53	Refining the use of adjuvant oxaliplatin in clinical stage II or III rectal adenocarcinoma.. *Journal of Clinical Oncology*, **2018**, 36, e15686-e15686	2.2
52	Comprehensive landscape of gene amplifications (amps) in tissue and circulating tumor DNA (ctDNA) in metastatic colorectal cancer (mCRC).. *Journal of Clinical Oncology*, **2019**, 37, 604-604	2.2
51	Systematic review of three decades of clinical trials in metastatic colorectal cancer: Making lemonade out of lemons?. *Journal of Clinical Oncology*, **2019**, 37, 656-656	2.2
50	Population pharmacokinetics (popPK) of Sym004 to evaluate the effect of intrinsic and extrinsic factors on exposure in metastatic colorectal cancer (mCRC).. *Journal of Clinical Oncology*, **2019**, 37, 496-496	2.2
49	Quantifying the evolution of tumor architecture using serial circulating tumor DNA.. *Journal of Clinical Oncology*, **2019**, 37, 600-600	2.2
48	Prediction model for detecting circulating tumor DNA (ctDNA) in metastatic colorectal cancer (mCRC).. *Journal of Clinical Oncology*, **2019**, 37, 3590-3590	2.2
47	The association between female hormonal supplementation and molecular types in colorectal cancer.. *Journal of Clinical Oncology*, **2019**, 37, e15133-e15133	2.2
46	Evaluation of complete pathological remission rates in surgically resected MSI-high metastatic colorectal cancers (mCRC).. *Journal of Clinical Oncology*, **2019**, 37, e15046-e15046	2.2
45	FOLFOXIRI versus doublet-regimens in the first-line therapy of MSI-S right-sided (RS) metastatic colorectal cancer (mCRC): A survival analysis.. *Journal of Clinical Oncology*, **2019**, 37, e15060-e15060	2.2
44	Identifying anti-EGFR (EGFRi) response subgroups using evidence of ctDNA selective pressure.. *Journal of Clinical Oncology*, **2019**, 37, 3587-3587	2.2
43	Reporting of patient (pt) characteristics (c) and use of stratification factors (SF) in phase III trials for metastatic colorectal cancer (mCRC): Urgent need for standardization.. *Journal of Clinical Oncology*, **2019**, 37, e15055-e15055	2.2
42	Meat consumption and BRAF mutation status in colorectal cancer.. *Journal of Clinical Oncology*, **2019**, 37, e15135-e15135	2.2
41	Association between gene fusions and anti-EGFR resistance signature in colorectal cancer.. *Journal of Clinical Oncology*, **2019**, 37, 3564-3564	2.2

40	Efficiency of biomarker screening for enriched metastatic colorectal cancer trials: The ATTACC program experience.. *Journal of Clinical Oncology*, **2014**, 32, 3619-3619	2.2
39	Association of CpG island methylator phenotype (CIMP) with inferior progression-free survival with anti-EGFR monoclonal antibody therapy in metastatic colorectal cancer.. *Journal of Clinical Oncology*, **2014**, 32, 3633-3633	2.2
38	Next-generation sequencing of advanced, relapsed colorectal adenocarcinoma (CRC) to reveal mutations affecting Wnt, MAPK and PI3K pathway signaling: Emergence of novel combinatorial strategies.. *Journal of Clinical Oncology*, **2015**, 33, 605-605	2.2
37	Multiple independent methods fail to confirm MET amplification rate reported in literature for metastatic colorectal cancer (mCRC).. *Journal of Clinical Oncology*, **2015**, 33, 572-572	2.2
36	Proteomic features of colorectal cancer independently predict relapse-free survival.. *Journal of Clinical Oncology*, **2015**, 33, 616-616	2.2
35	Acquired mutations in MAPK signaling pathway following initial pharmacological response in BRAF-mutated metastatic colorectal cancer (mCRC).. *Journal of Clinical Oncology*, **2015**, 33, 629-629	2.2
34	Proteomic signatures of colorectal cancer to identify distinct and reproducible subgroups independent of oncogenic mutations.. *Journal of Clinical Oncology*, **2015**, 33, 580-580	2.2
33	Proteomic signatures of colorectal cancer to identify distinct and reproducible subgroups and to reflect prognosis.. *Journal of Clinical Oncology*, **2015**, 33, 3612-3612	2.2
32	A phase II study of nab-paclitaxel in refractory CIMP-high metastatic colorectal cancer.. *Journal of Clinical Oncology*, **2015**, 33, e14700-e14700	2.2
31	Clinical utility of a circulating cell-free DNA assay for clinical trial enrollment in refractory metastatic colorectal cancer patients.. *Journal of Clinical Oncology*, **2015**, 33, 3601-3601	2.2
30	Predictors of clonal evolution in metastatic colorectal cancer patients.. *Journal of Clinical Oncology*, **2015**, 33, 3604-3604	2.2
29	Recurrent parathyroid carcinoma and the need for molecular profiling to aid in prognostication and therapeutics.. *Journal of Clinical Oncology*, **2015**, 33, e17012-e17012	2.2
28	Phase II study of bevacizumab combined with capecitabine and oxaliplatin in patients with advanced adenocarcinoma of the small bowel or ampulla of vater.. *Journal of Clinical Oncology*, **2016**, 34, 144-144	2.2
27	Association of FBXW7 missense mutations (mt) with unfavorable prognosis in metastatic colorectal cancer (mCRC) patients (pts).. *Journal of Clinical Oncology*, **2016**, 34, 3607-3607	2.2
26	Identification of novel EGFR ectodomain mutations based on a large database of clinical circulating cell-free DNA sequencing tests.. *Journal of Clinical Oncology*, **2016**, 34, e23167-e23167	2.2
25	Arginine methylation of EGFR in circulating tumor cells: A new biomarker for predicting resistance to anti-EGFR agents.. *Journal of Clinical Oncology*, **2017**, 35, 3590-3590	2.2
24	DNA sequencing of the small bowel adenocarcinomas to identify targetable ErbB2 mutations.. *Journal of Clinical Oncology*, **2017**, 35, e15800-e15800	2.2
23	Molecular characterization of TP53 mutations and copy number change in colorectal cancers.. *Journal of Clinical Oncology*, **2017**, 35, e15143-e15143	2.2

22	Liquid biopsies of plasma exosomal nucleic acids, plasma cell-free DNA, and survival of patients with advanced cancers.. *Journal of Clinical Oncology*, **2017**, 35, 11551-11551	2.2
21	Simultaneous molecular alterations in solid tumors with IDH1 or IDH2 mutations.. *Journal of Clinical Oncology*, **2017**, 35, 11609-11609	2.2
20	Systemic Therapy for Non-operable Colorectal Cancer Metastases **2009**, 1-8	
19	Association of PTEN loss and local recurrence in stage II-III colon cancer.. *Journal of Clinical Oncology*, **2011**, 29, 399-399	2.2
18	Preoperative radiation therapy with concurrent capecitabine, bevacizumab, and erlotinib for rectal adenocarcinoma: A phase I trial.. *Journal of Clinical Oncology*, **2012**, 30, 544-544	2.2
17	Relationship of Src activity and prior oxaliplatin on outcomes after hepatectomy for metastatic colorectal cancer.. *Journal of Clinical Oncology*, **2012**, 30, 3561-3561	2.2
16	Progression-free survival in metastatic, BRAF-mutated colorectal cancer.. *Journal of Clinical Oncology*, **2013**, 31, 458-458	2.2
15	Molecular characteristics of complete PTEN loss in metastatic colorectal cancer.. *Journal of Clinical Oncology*, **2013**, 31, 389-389	2.2
14	Association of colorectal cancer intrinsic subtypes with prognosis, chemotherapy response, deficient mismatch repair, and epithelial to mesenchymal transition (EMT).. *Journal of Clinical Oncology*, **2013**, 31, 3530-3530	2.2
13	Association of prior treatment with anti-EGFR monoclonal antibodies with downregulation of circulating TRAIL and upregulation of EGFR and VEGF family ligands in metastatic colorectal cancer.. *Journal of Clinical Oncology*, **2014**, 32, 452-452	2.2
12	Colorectal high-grade neuroendocrine carcinoma: A single institution experience.. *Journal of Clinical Oncology*, **2014**, 32, 540-540	2.2
11	Il-8 as an underutilized prognostic factor in metastatic colorectal cancer.. *Journal of Clinical Oncology*, **2014**, 32, 409-409	2.2
10	Association between KRAS mutation and lung metastasis in advanced colorectal cancer.. *Journal of Clinical Oncology*, **2014**, 32, 494-494	2.2
9	Efficiency of biomarker screening for enriched metastatic colorectal cancer trials: The ATTACC program experience.. *Journal of Clinical Oncology*, **2014**, 32, 450-450	2.2
8	A novel clinical tool to estimate risk of false negative KRAS mutation in circulating tumor DNA testing.. *Journal of Clinical Oncology*, **2021**, 39, 3594-3594	2.2
7	Addition of RAS Mutation Status May Strengthen the Predictive Model for Progression of Indeterminate Pulmonary Nodules. *Annals of Surgery*, **2016**, 264, e7	7.8
6	Two phase I, pharmacokinetic, and pharmacodynamic studies of DFP-10917, a novel nucleoside analog with 14-day and 7-day continuous infusion schedules. *Investigational New Drugs*, **2019**, 37, 76-86	4.3
5	Epigenetic regulation of the Wnt-signaling pathway in CIMP-H BRAFV600E mCRC.. *Journal of Clinical Oncology*, **2021**, 39, 110-110	2.2

4	Real-world genomic and treatment landscape in advanced colorectal cancer identifies treatment differences pre- and post-ctDNA genomic profiling.. *Journal of Clinical Oncology*, **2021**, 39, 39-39	2.2
3	Phase II study of DFP-10917, a deoxycytidine analog, given by 14-day continuous intravenous infusion for chemotherapy-refractory advanced colorectal cancer. *Investigational New Drugs*, **2018**, 36, 895-902	4.3
2	Novel targets for systemic therapy of colorectal cancer. *Clinical Advances in Hematology and Oncology*, **2008**, 6, 38-40	0.6
1	Clinical and pathologic features correlated with rare favorable survival in patients with mutated colorectal cancer.. *Journal of Gastrointestinal Oncology*, **2022**, 13, 647-656	2.8